Core Viewpoint - The release of the National Medical Insurance Administration's guidelines on surgical and treatment auxiliary medical service pricing is expected to drive the clinical adoption of innovative technologies, particularly in the field of surgical robotics, benefiting companies like Precision Medicine-B (02675) [1] Company Summary - Precision Medicine-B (02675) has seen its stock price increase by over 9%, reaching 64.8 HKD with a trading volume of 23.0585 million HKD [1] - The company is recognized as a leading surgical robotics firm in China's medical device industry, focusing on the design, development, and manufacturing of surgical robots [1] - According to Frost & Sullivan, Precision Medicine is the first company in China and the second globally to obtain regulatory approval for multi-port, single-port, and natural orifice surgical robots [1] Industry Summary - The National Medical Insurance Administration has issued a guideline that includes 37 pricing projects, 5 additional charge items, and 1 expansion item, focusing on advanced medical technologies such as 3D printing and robotic surgery [1] - The implementation of these guidelines is expected to standardize the pricing and project establishment for surgical robots across provinces, promoting the clinical use of innovative technologies and driving demand for terminal equipment and surgical assistance [1]